Revelation Biosciences Surges After Encouraging Data From Allergic Rhinitis Study

 

• Revelation Biosciences Inc 
  REVB+75.3%+ Free Alerts
   announced topline data for its Phase 1b CLEAR study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.
• The study met the primary endpoint evaluating the effects of REVTx-99b versus placebo on safety and tolerability. 
• Exploratory endpoints for efficacy were not met, including no reduction in allergy symptoms and increase in peak nasal inspiratory flow versus placebo. 
• Revelation management plans to evaluate the future development of this and other ongoing programs.
• REVTx-99b is a proprietary intranasal formulation in development for managing allergic rhinitis symptoms, including chronic nasal congestion. 
• Phase 2b viral challenge study data announced in March showed that REVTx-99a did not meet its primary endpoint, the area under the curve of viral load by quantitative RT-PCR from nasopharyngeal swabs.

https://www.benzinga.com/general/biotech/22/07/28183340/revelation-biosciences-surges-after-encouraging-data-from-allergic-rhinitis-study